SCA
KRTX

Snowden Capital Advisors’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Snowden Capital Advisors’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,231
Closed -$706K – 1221
2023
Q4 		$706K Sell
2,231
-22
-1% -$4.28K 0.03% 546
2023
Q3 		$381K Sell
2,253
-46
-2% -$8.65K 0.02% 768
2023
Q2 		$499K Sell
2,299
-15
-0.6% -$3.21K 0.02% 734
2023
Q1 		$420K Buy
2,314
+743
+47% +$142K 0.02% 803
2022
Q4 		$309K Buy
1,571
+676
+76% +$145K 0.01% 903
2022
Q3 		$201K Buy
+895
New +$181K 0.01% 1037

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Snowden Capital Advisors's KRTX Position: Q1 2024 in Review

Snowden Capital Advisors sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 2,231 shares — an estimated $706K sold.

Snowden Capital Advisors first reported a position in KRTX in Q3 2022 and held it in 6 quarters. The position peaked at $706K in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • Snowden Capital Advisors reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Snowden Capital Advisors sold 2,231 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $706K.
  • Snowden Capital Advisors first reported a position in Karuna Therapeutics, Inc. Common Stock in Q3 2022 and held it in 6 quarters.
  • Snowden Capital Advisors's Karuna Therapeutics, Inc. Common Stock position peaked at $706K in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Snowden Capital Advisors's 13F filing for Q1 2024, filed 15 May 2024.